Immunic (IMUX) Projected to Post Earnings on Thursday

Immunic (NASDAQ:IMUX - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Immunic Stock Performance

Shares of IMUX traded up $0.10 during mid-day trading on Friday, hitting $1.28. 1,725,338 shares of the stock were exchanged, compared to its average volume of 992,503. The company has a market cap of $114.85 million, a PE ratio of -1.04 and a beta of 1.87. Immunic has a 52-week low of $0.92 and a 52-week high of $2.11. The firm has a 50-day moving average of $1.02 and a two-hundred day moving average of $1.26.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on IMUX shares. StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a report on Monday, February 10th. D. Boral Capital restated a "buy" rating and set a $17.00 price target on shares of Immunic in a report on Thursday. Finally, HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Immunic in a report on Friday. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $12.67.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.